The remaining two variants included one upstream variant at the MSMB locus that was annotated as pathogenic for hereditary prostate cancer, as well as one stop-gain variant within DUOXA2 that was annotated as pathogenic for thyroid dyshormonogenesis. This evidence concerns the gene DUOXA2 and prostate carcinoma.